for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CryoPort Inc

CYRX.OQ

Latest Trade

14.40USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.30

 - 

25.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.40
Open
--
Volume
--
3M AVG Volume
13.99
Today's High
--
Today's Low
--
52 Week High
25.00
52 Week Low
8.30
Shares Out (MIL)
35.59
Market Cap (MIL)
500.79
Forward P/E
-55.33
Dividend (Yield %)
--

Latest Developments

More

Cryoport Authorizes Share Repurchase Program And Presenting At Upcoming Investor Conferences

Cryoport Q2 Loss Per Share $0.08

Cryoport Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CryoPort Inc

Cryoport, Inc. (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients. The Company's Cryoport Express Solution includes a cloud-based logistics operating platform, which is branded as the Cryoportal. The Company's Cryoport Express Solutions are made up of the Cryoportal software platform, Cryoport Express Shippers, Cryoport Express Smart Pak data loggers and its life sciences cold chain logistics expertise. The Cryoportal is used by the Company, its clients and its business partners to automate the entry of orders, prepare customs documentation, and to facilitate status and location monitoring of shipped orders while in transit.

Industry

Misc. Transportation

Contact Info

17305 Daimler St

+1.949.2321900

https://www.cryoport.com/

Executive Leadership

Jerrell W. Shelton

Chairman of the Board, President, Chief Executive Officer

Robert S. Stefanovich

Chief Financial Officer, Treasurer, Corporate Secretary

Daniel M. Hancock

Director

Robert J. Hariri

Independent Director

Ramkumar Mandalam

Independent Director

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.050

2017

-0.340

2018

-0.340

2019(E)

-0.254
Price To Earnings (TTM)
--
Price To Sales (TTM)
19.19
Price To Book (MRQ)
4.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.58
LT Debt To Equity (MRQ)
13.56
Return on Investment (TTM)
-12.26
Return on Equity (TTM)
-11.58

Latest News

Latest News

BRIEF-Cryoport Revenue Grows 48 Pct For First Quarter

* CRYOPORT REVENUE GROWS 48% FOR FIRST QUARTER; 62% IN BIOPHARMA

BRIEF-Cryoport Qtrly loss Per Share $0.09

* CRYOPORT REPORTS 56% REVENUE GROWTH FOR FISCAL YEAR ENDED DECEMBER 31, 2017

BRIEF-Cryoport revenue up 52 percent driven by BioPharma

* Revenue increased 52 percent to $3.0 million for three month period ended September 30, 2017

BRIEF-Cryoport to support commercial launch of Kite Pharma's CAR-T therapy, axi-cel​

* Cryoport Inc - Cryoport selected to support potential commercial launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel

BRIEF-Cryoport reports Q2 loss per share $0.08

* Cryoport revenue up 52% for the second quarter of 2017, driven by biopharma

BRIEF-Cryoport says Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support

* Cryoport - Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy Source text for Eikon: Further company coverage:

BRIEF-Cryoport expands agreement with Sanaria to support grant awards with U.S. National institutes of Health, U.S. army

* Cryoport expands agreement with Sanaria to support grant awards with u.s. National institutes of health and u.s. Army

BRIEF-Cryoport Q1 GAAP loss per share $0.10

* Q1 revenue rose 74 percent to $2.7 million Source text for Eikon: Further company coverage:

BRIEF-Cryoport announces pricing of public offering of common stock

* Cryoport announces pricing of public offering of common stock

BRIEF-Cryoport announces proposed public offering of common stock

* Cryoport announces proposed public offering of common stock

BRIEF-Cryoport posts qtrly loss $0.25 per share

* Cryoport revenue continues to climb, reporting 53 pct growth for the quarter ended December 31, 2016

BRIEF-Cryoport Inc says launch of Cryostork next flight out for reproductive health market

* Cryoport Inc says launch of Cryostork next flight out for reproductive health market Source text for Eikon: Further company coverage:

BRIEF-Cryoport reports 38 pct rise in Q2 revenue

* Net loss attributable to common stockholders for three month period ended September 30, 2016 were $2.2 million, or $0.14 per share

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up